Senior Vice President CMC, NeRRe Therapeutics
Currently SVP, CMC for two clinical-stage biotech companies, KaNDy Therapeutics and NeRRe Therapeutics, with accountability for the overall CMC strategy and delivery for both companies. Previously spent over 30 years at GlaxoSmithKline in leadership roles in CMC product development, manufacturing and quality.
Member of Innovate UK Medicines Manufacturing Challenge Advisory Group, the Knowledge Transfer Network Health Stakeholder Board and has been influential in aligning Pharma and UK Government on future areas for investment as part of the delivery of the UK Life Sciences Industrial Strategy. Advisor to the Board for the Academy of Pharmaceutical Sciences, UK.